$61.80
1.48% yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
US10806X1028
Symbol
BBIO

BridgeBio Pharma Inc Stock price

$61.80
+7.58 13.98% 1M
+25.98 72.53% 6M
+34.36 125.22% YTD
+35.92 138.79% 1Y
+52.63 573.94% 3Y
+21.45 53.16% 5Y
+34.25 124.32% 10Y
+34.25 124.32% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
-0.93 1.48%
ISIN
US10806X1028
Symbol
BBIO
Industry

New AI Insights on BridgeBio Pharma Inc Insights AI Insights on BridgeBio Pharma Inc

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$12.1b
Enterprise Value
$14.1b
Net debt
$2.0b
Cash
$645.9m
Shares outstanding
192.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
34.2 | 24.4
EV/Sales
39.9 | 28.5
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-159.7%
Return on Equity
36.5%
ROCE
-76.1%
ROIC
-188.7%
Debt/Equity
-1.4
Financials (TTM | estimate)
Revenue
$353.8m | $495.6m
EBITDA
$-589.6m | $-459.4m
EBIT
$-595.0m | $-505.5m
Net Income
$-797.1m | $-684.7m
Free Cash Flow
$-597.6m
Growth (TTM | estimate)
Revenue
62.5% | 123.3%
EBITDA
-12.0% | 19.6%
EBIT
-11.7% | 12.5%
Net Income
-81.6% | -27.8%
Free Cash Flow
-31.0%
Margin (TTM | estimate)
Gross
95.8%
EBITDA
-166.7% | -92.7%
EBIT
-168.2%
Net
-225.3% | -138.2%
Free Cash Flow
-168.9%
More
EPS
$-4.2
FCF per Share
$-3.1
Short interest
15.0%
Employees
728
Rev per Employee
$300.0k
Show more

Is BridgeBio Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

BridgeBio Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a BridgeBio Pharma Inc forecast:

23x Buy
92%
2x Hold
8%

Analyst Opinions

25 Analysts have issued a BridgeBio Pharma Inc forecast:

Buy
92%
Hold
8%

Financial data from BridgeBio Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
354 354
62% 62%
100%
- Direct Costs 15 15
525% 525%
4%
339 339
57% 57%
96%
- Selling and Administrative Expenses 468 468
94% 94%
132%
- Research and Development Expense 466 466
8% 8%
132%
-590 -590
12% 12%
-167%
- Depreciation and Amortization 5.37 5.37
15% 15%
2%
EBIT (Operating Income) EBIT -595 -595
12% 12%
-168%
Net Profit -797 -797
82% 82%
-225%

In millions USD.

Don't miss a Thing! We will send you all news about BridgeBio Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BridgeBio Pharma Inc Stock News

Neutral
GlobeNewsWire
about 10 hours ago
Following a challenge submitted by Pfizer, Inc., BBB National Programs' National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enforcement action for failure to participate in the National Advertising Division (NAD) inquiry. Following a challenge submitted by Pfizer, Inc., BBB National Programs' National Advertising Division wi...
Neutral
GlobeNewsWire
4 days ago
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences:
Positive
Market Watch
5 days ago
The volatile sector is seeing greater stability, and these four stocks can profit.
More BridgeBio Pharma Inc News

Company Profile

BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

Head office United States
CEO Neil Kumar
Employees 728
Founded 2015
Website bridgebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today